Amneal reports fourth quarter and full year 2022 financial results

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) announced its results today for the fourth quarter and full year ended december 31, 2022. “2022 was a year of solid execution and very good progress in advancing key strategic priorities marked by a robust cadence of new innovations in generics, scaling our injectables portfolio, advancing our specialty pipeline and entering the u.s. biosimilars market.
AMRX Ratings Summary
AMRX Quant Ranking